🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Masoud Azodi

Yale University

ORCID: 0000-0002-0570-8089

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability”.

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

Cancer(2021)10.1002/cncr.34025

N/A

2.4DataRank · unranked

80 citations

Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli +28 more

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)

Annals of Oncology(2021)10.1016/j.annonc.2021.04.013

N/A

1.9DataRank · unranked

50 citations

Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli +28 more

Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status

UNC Libraries(2020)10.17615/6wxj-0g75

N/A

0DataRank · unranked

0 citations

Claudine Isaacs, Patrick M. Sluss, Phuong Mai, Wendy R. Brewster, Gustavo C. Rodriguez +25 more

Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.11.014

N/A

0DataRank · unranked

30 citations

Stefania Bellone, Diego Manavella, Levent Mutlu, Blair McNamara, Tobias M.P. Hartwich +17 more

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.05.005

N/A

0DataRank · unranked

25 citations

Paola Manara, Diego Manavella, Stefania Bellone, Tobias M.P. Hartwich, Justin Harold +17 more

In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0126

N/A

0DataRank · unranked

8 citations

Diego Manavella, Stefania Bellone, Blair McNamara, Justin Harold, Dennis Mauricio +17 more

Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.03.009

N/A

0DataRank · unranked

4 citations

Justin Harold, Diego Manavella, Stefania Bellone, Levent Mutlu, Tobias M.P. Hartwich +24 more

Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2321898121

N/A

0DataRank · unranked

18 citations

Kyungjo Jeong, Mari K. Halle, Camilla Krakstad, Blair McNamara, Michelle Greenman +33 more

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

Frontiers in Oncology(2020)10.3389/fonc.2020.00118

N/A

0DataRank · unranked

64 citations

Salvatore Lopez, Burak Zeybek, Stefania Bellone, Elena Bonazzoli, Silvia Pelligra +17 more

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2

Clinical & Experimental Metastasis(2024)10.1007/s10585-024-10297-z

N/A

0DataRank · unranked

9 citations

Blair McNamara, Stefania Bellone, Diego Manavella, Cem Demirkiran, Michelle Greenman +16 more

Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.06.484

N/A

0DataRank · unranked

4 citations

Stefania Bellone, Luca Zammataro, Barbara Gnutti, Adele Guglielmi, Silvia Pelligra +15 more